日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer

氧化磷酸化是化疗耐药性三阴性乳腺癌的代谢弱点

Kurt W Evans, Erkan Yuca, Stephen S Scott, Ming Zhao, Natalia Paez Arango, Christian X Cruz Pico, Turcin Saridogan, Maryam Shariati, Caleb A Class, Christopher A Bristow, Christopher P Vellano, Xiaofeng Zheng, Ana Maria Gonzalez-Angulo, Xiaoping Su, Coya Tapia, Ken Chen, Argun Akcakanat, Bora Lim, D

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

Selinexor (KPT-330) 在三阴性乳腺癌临床前模型中表现出抗肿瘤功效

Natalia Paez Arango, Erkan Yuca, Ming Zhao, Kurt W Evans, Stephen Scott, Charissa Kim, Ana Maria Gonzalez-Angulo, Filip Janku, Naoto T Ueno, Debu Tripathy, Argun Akcakanat, Aung Naing, Funda Meric-Bernstam

Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel

CDK4/6 抑制对获得性紫杉醇耐药的激素受体阳性/人类表皮生长因子受体 2 阴性乳腺癌细胞的影响

Adriana Priscila Trapé, Shuying Liu, Andrea Carolina Cortes, Naoto T Ueno, Ana Maria Gonzalez-Angulo

Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy

血管周围 M2 巨噬细胞刺激化疗后肿瘤复发

Russell Hughes, Bin-Zhi Qian, Charlotte Rowan, Munitta Muthana, Ioanna Keklikoglou, Oakley C Olson, Simon Tazzyman, Sarah Danson, Christina Addison, Mark Clemons, Ana Maria Gonzalez-Angulo, Johanna A Joyce, Michele De Palma, Jeffrey W Pollard, Claire E Lewis

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

接受过治疗的晚期雌激素受体阳性乳腺癌中出现组成性活性雌激素受体-α 突变

Rinath Jeselsohn #, Roman Yelensky #, Gilles Buchwalter #, Garrett Frampton #, Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo, Jaime Ferrer-Lozano, Jose A Perez-Fidalgo, Massimo Cristofanilli, Henry Gómez, Carlos L Arteaga, Jennifer Giltnane, Justin M Balko, Maureen T Cronin, Mirna Jarosz, James Su

Influence of biospecimen variables on proteomic biomarkers in breast cancer

生物样本变量对乳腺癌蛋白质组生物标志物的影响

Funda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, Aysegul Sahin, Emily Tarco, Selin Carkaci, Beatriz E Adrada, Gopal Singh, Kim-Anh Do, Zerzhinski M Garces, Elizabeth Mittendorf, Gildy Babiera, Isabelle Bedrosian, Rosa Hwang, Savitri Krishnamurthy, William F Symmans, Ana Maria Gonzalez-Angulo, Gor

Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer

过氧化物酶-1 保护雌激素受体 α 免受氧化应激诱导的抑制,并且是乳腺癌预后良好的蛋白质生物标志物

Patrick C O'Leary, Marta Terrile, Malgorzata Bajor, Pawel Gaj, Bryan T Hennessy, Gordon B Mills, Agnieszka Zagozdzon, Darran P O'Connor, Donal J Brennan, Kate Connor, Jane Li, Ana Maria Gonzalez-Angulo, Han-Dong Sun, Jian-Xin Pu, Fredrik Pontén, Mathias Uhlén, Karin Jirström, Dominika A Nowis, John

Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC

开发针对 Fn14 的人类丝氨酸蛋白酶疗法,并确定 Fn14 是 TNBC 中过表达的新靶点

Hong Zhou, Khalid A Mohamedali, Ana Maria Gonzalez-Angulo, Yu Cao, Mary Migliorini, Lawrence H Cheung, Janine LoBello, Xiudong Lei, Yuan Qi, Walter N Hittelman, Jeffrey A Winkles, Nhan L Tran, Michael G Rosenblum

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

三阴性乳腺癌中的 MYC 通路激活与 CDK 抑制共同致死

Dai Horiuchi, Leonard Kusdra, Noelle E Huskey, Sanjay Chandriani, Marc E Lenburg, Ana Maria Gonzalez-Angulo, Katelyn J Creasman, Alexey V Bazarov, James W Smyth, Sarah E Davis, Paul Yaswen, Gordon B Mills, Laura J Esserman, Andrei Goga

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors

PIK3CA/PTEN 突变和 Akt 激活作为对变构 mTOR 抑制剂敏感性的标志

Funda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, Kim-Anh Do, Takafumi Sangai, Farrell Adkins, Ana Maria Gonzalez-Angulo, Asif Rashid, Katherine Crosby, Mei Dong, Alexandria T Phan, Robert A Wolff, Sanjay Gupta, Gordon B Mills, James Yao